304 related articles for article (PubMed ID: 25934338)
21. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
22. Vaccines versus immunotherapy: overview of approaches in deciding between options.
Dalgleish AG
Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
[TBL] [Abstract][Full Text] [Related]
23. Promising approaches in cancer immunotherapy.
Taefehshokr N; Baradaran B; Baghbanzadeh A; Taefehshokr S
Immunobiology; 2020 Mar; 225(2):151875. PubMed ID: 31812343
[TBL] [Abstract][Full Text] [Related]
24. Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
Huang MA; Krishnadas DK; Lucas KG
J Immunol Res; 2015; 2015():675269. PubMed ID: 26587548
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies for cancer immunotherapy.
Weiner LM; Dhodapkar MV; Ferrone S
Lancet; 2009 Mar; 373(9668):1033-40. PubMed ID: 19304016
[TBL] [Abstract][Full Text] [Related]
26. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in human colorectal cancer: Challenges and prospective.
Sun X; Suo J; Yan J
World J Gastroenterol; 2016 Jul; 22(28):6362-72. PubMed ID: 27605872
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy.
White RL; Amin A
Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
[TBL] [Abstract][Full Text] [Related]
29. [Immunological tumor therapy].
Dietrich K; Theobald M
Internist (Berl); 2015 Aug; 56(8):907-16; quiz 917. PubMed ID: 26187335
[TBL] [Abstract][Full Text] [Related]
30. Are mimotope vaccines a good alternative to monoclonal antibodies?
Pourjafar M; Samadi P; Khoshinani HM; Saidijam M
Immunotherapy; 2019 Jun; 11(9):795-800. PubMed ID: 31094256
[TBL] [Abstract][Full Text] [Related]
31. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
Brahmer JR
Semin Oncol; 2014 Feb; 41(1):126-32. PubMed ID: 24565586
[TBL] [Abstract][Full Text] [Related]
33. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
34. Harnessing the power of the immune system to target cancer.
Lizée G; Overwijk WW; Radvanyi L; Gao J; Sharma P; Hwu P
Annu Rev Med; 2013; 64():71-90. PubMed ID: 23092383
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy Approaches in Cancer Treatment.
Klener P; Otáhal P; Lateckova L; Klener P
Curr Pharm Biotechnol; 2015; 16(9):771-81. PubMed ID: 26087990
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
37. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells in cancer immunotherapy.
Vulink A; Radford KJ; Melief C; Hart DN
Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
[TBL] [Abstract][Full Text] [Related]
39. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
40. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E
Front Immunol; 2018; 9():394. PubMed ID: 29599770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
